## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.3% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($25.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD)**
- Source: Simply Wall Street | 20251216T200844 | Somewhat-Bullish | Relevance: 100%
- Acadia Pharmaceuticals received FDA approval for DAYBUE STIX, a new dye- and preservative-free powder formulation of trofinetide for Rett syndrome, offering improved flexibility over the existing oral solution. While this could enhance patient retention and supports the Rett franchise, investors should note that the company's near-term earnings primarily rely on NUPLAZID. Analysts like H.C. Wainwright have raised price targets, reflecting optimism about the new formulation's long-term impact on patient retention and Acadia's revenue guidance.

**2. FDA Approves Acadia Pharmaceuticals’ Daybue Stix for Treating Rett Syndrome**
- Source: GeneOnline | 20251215T110940 | Bullish | Relevance: 100%
- The U.S. FDA has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide) for the treatment of Rett syndrome, a rare neurological disorder that primarily affects females. This approval provides a new therapeutic option for patients and caregivers, targeting the underlying symptoms of the condition. The decision follows a review of clinical trial data on the safety and efficacy of trofinetide.

**3. Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright**
- Source: Investing.com India | 20251216T130844 | Bullish | Relevance: 100%
- H.C. Wainwright increased its price target on Acadia Pharmaceuticals (NASDAQ:ACAD) to $37 from $32, maintaining a Buy rating after the launch of DAYBUE STIX, a new powder formulation of the company’s Rett syndrome drug. This new formulation is expected to improve patient retention and growth, leading to revised penetration assumptions and the higher price target. InvestingPro data suggests ACAD is currently undervalued and possesses strong financials with more cash than debt.

**4. FDA approves Acadia’s Daybue Stix for Rett syndrome treatment**
- Source: Pharmaceutical Technology | 20251215T220940 | Bullish | Relevance: 100%
- The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a new dye and preservative-free powder formulation, for treating Rett syndrome in patients aged two years and older. This new formulation aims to offer greater flexibility in administration regarding taste and dosage volume, maintaining the same efficacy and safety profile as the existing Daybue oral solution. Daybue Stix will be available in limited quantities starting in the first quarter of 2026, with wider distribution expected early in the second quarter.

**5. FDA approves Acadia’s Daybue Stix for Rett syndrome**
- Source: Pharmaceutical Business review - | 20251215T220844 | Bullish | Relevance: 100%
- The U.S. Food and Drug Administration (FDA) has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a new powder formulation for the treatment of Rett syndrome, designed for adult and pediatric patients aged two years and older. This new formulation offers an alternative administration method with comparable efficacy and safety to the existing Daybue oral solution. Daybue Stix will be gradually rolled out starting in the first quarter of 2026, alongside the continued availability of the oral solution.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | HC Wainwright & | $37 | $32 | +16% |
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | HC Wainwright & | main | Buy |
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (3 raises, avg +14%). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 33.0 |
| Current P/E | 32.9 |
| YoY Growth | -0.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 1.7pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.27% (CS: 54) | Neutral |
| RSI_14 | 64.5 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.145x | Above |
| vs SMA200 | 1.256x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $26.80
- **Stop Loss:** $25.06 (6.5% risk)
- **Target:** $28.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 574
- **Position Value:** $15,383.20
- **Portfolio %:** 15.38%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*